SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : RAINFOREST CAFE
RAIN 6.190-1.1%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dennis Vail who wrote (3278)10/3/1997 2:43:00 AM
From: Czechsinthemail   of 4704
 
Dennis,

Here are my best suggestions for stocks likely to show big moves between now and late December. All three have sold off significantly from their highs, so you have a lot of upside that has already been carved out by prior price history. They are fairly low priced so that you should get a big percentage gain off any appreciation. Two of the three dominate their industry, and the third is a biotech company with a major product due for FDA review by the end of this year.

Cymer (CYMI) 27 5/8. Cymer makes excimer lasers for state of the art semiconductor equipment. Their lasers are estimated to be in 80 - 90% of the new DUV steppers being produced to create 0.25 micron semiconductor designs. They have had incredible growth and apparently have the best and the brightest in the laser field in their shop.

Rational Software (RATL) 15 1/2. Rational produces software for developing and testing object oriented software. They dominate the field not only in terms of the amount of business they do, but also in having the brightest people in the O-O field working for them.

DepoTech (DEPO) 13 1/4. DepoTech is a biopharmaceutical company that specializes in drug delivery systems based upon DepoFoam technology. Essentially, it allows time-release of drugs over a period of days or weeks. DepoCyt, a cancer drug, has completed its clinical trials and is awaiting FDA approval, which is anticipated by year end. Since DepoCyt had strong clinical results and is essentially a reformulation of an already approved drug, the likelihood for approval is very high. Current estimates are that the company will shift into the profitable biotech echelon next year, based on sales of DepoCyt.

You can check the SI threads for each of them and get a lot of good info.

Good luck,
Baird
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News